Erzhi Tiangui Granules Improve In Vitro Fertilization Outcomes in Infertile Women with Advanced Age
Table 1
Characteristics of study participants.
Parameter
EZTG group
Placebo group
value
Patients
48
49
—
Age (years)
38.92 ± 4.43
37.61 ± 4.22
0.139
BMI (kg/m2)
25.42 ± 5.73
24.05 ± 4.33
0.187
AMH (ng/ml)
1.75 ± 0.52
1.90 ± 0.41
0.118
Baseline day 3 FSH (mIU/ml)
10.53 ± 1.72
10.00 ± 2.16
0.185
Baseline day 3 E2 (pg/ml)
49.70 ± 11.83
53.50 ± 11.20
0.108
E2 on HCG day (pg/ml)
4258.75 ± 1135.11
4509.83 ± 1249.35
0.303
P on HCG day (ng/ml)
1.29 ± 0.26
1.39 ± 0.33
0.101
TCM clinical syndrome score
13.24 ± 2.17
14.60 ± 3.52
0.155
Gn days (d)
9.26 ± 2.28
9.78 ± 2.79
0.318
Gn doses (U)
3450.75 ± 1237.55
3625.85 ± 1803.25
0.579
Retrieved oocytes (n)
8.13 ± 3.22
7.85 ± 2.55
0.636
No. of 2PN fertilization
6.91 ± 2.87
5.87 ± 2.66
0.067
No. of 2PN cleavage
6.11 ± 2.13
5.39 ± 2.74
0.152
No. of good quality embryos
4.13 ± 2.83
2.88 ± 1.85
0.011
Transferred embryos per cycle
1.75 ± 0.53
1.80 ± 0.50
0.634
Cumulative pregnancy rate
32.4% (36/111)
28.7% (27/94)
0.566
AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; E2, estradiol; P, progesterone; TCM, traditional Chinese medicine; Gn, gonadotropin. indicates a statistically significant difference between the 2 groups of data. The value in bold indicates that the number of high-quality embryos was significantly increased in the EZTG group compared with the placebo group.
